Drug delivery through the blood-brain barrier

https://doi.org/10.1016/0169-409X(96)00011-7Get rights and content

Abstract

Specific mechanisms functioning at the blood-brain barrier (BBB) for the permeation of drugs and natural compounds in the blood-to-brain and brain-to-blood directions are described. Various anionic compounds are transported by monocarboxylic acid-specific transporter(s). One such transporter is MCT1, which transports lactic acid, short-chain acids and others. As regards cationic compounds, at least two types of transporter for amines and cationic drugs appear to operate. Relatively small peptides are also transported by carrier-mediated transport mechanisms. Peptides can be delivered into the brain by absorptive-mediated endocytosis (transcytosis), which is specific to positively charged peptides or peptides into which positive charges have been introduced. For more specific delivery into brain, receptor-mediated endocytosis for peptides carrying both BBB-transporting and pharmacologically active moieties is promising. Furthermore, specific drug efflux from the brain mediated by P-glycoprotein is described. The utilization and/or avoidance of these specific mechanisms at the BBB should make it possible to enhance delivery of drugs into the brain, or to decrease the apparent permeability in order to prevent undesirable side effects in the central nervous system.

References (123)

  • T. Komai et al.

    Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture

    Biochem. Pharmacol.

    (1992)
  • A. Kurihara et al.

    Uptake of propranolol by microvessels isolated from bovine brain

    J. Pharm. Sci.

    (1987)
  • L.H. Lash et al.

    Renal glutathione transport. Characteristics of the sodium-dependent system in the basolateral membrane

    J. Biol. Chem.

    (1984)
  • B.V. Zlokovic et al.

    Kinetics of arginine-vasopressin uptake at the blood-brain barrier

    Biochim. Biophys. Acta

    (1990)
  • C.M. Barrera et al.

    d-[Alal]-peptide T-amide is transported from blood to brain by a saturable system

    Brain Res. Bull.

    (1987)
  • W.A. Banks et al.

    Evidence that 125I-N-Tyr-delta sleeping peptide crosses the blood-brain barrier by a non-competitive mechanism

    Brain Res.

    (1984)
  • W.A. Banks et al.

    Bidirectional transport of interleukin-1 across the blood-brain barrier

    Brain Res. Bull.

    (1989)
  • K. Miyamoto et al.

    Sequence, tissue distribution and developmental changes in rat intestinal oligopeptide transporter

    Biochim. Biophys. Acta

    (1996)
  • A.K. Kumagai et al.

    Absorptive-mediated endocytosis of cationized albumin and a β-endorphin-cationized albumin chimeric peptide by isolated brain capillaries

    J. Biol. Chem.

    (1987)
  • N. Tsuzuki et al.

    Adamantanes as a brain-directed drug carrier for poorly absorbed drug: Antinociceptive effects of [d-ala2]leu-enkephalin derivatives conjugated with the 1-adamantane moiety

    Biochem. Pharmacol.

    (1991)
  • R.L. Juliano et al.

    Surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

    Biochim. Biophys. Acta

    (1976)
  • I. Tamai et al.

    Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells

    J. Biol. Chem.

    (1991)
  • A.R. Safa et al.

    Vinblastine photoaffinity labeling of a high molecular weight surface membrane glycoprotein specific for multidrug-resistant cells

    J. Biol. Chem.

    (1986)
  • A. Kakee et al.

    Organic anion transport system acting as an efflux pump at the blood-brain barrier: Demonstration by a newly developed brain efflux index (BEI) method

  • K. Ohno et al.

    Lower limits of cerebrovascular permeability to non-electrolytes in the conscious rat

    Am. J. Physiol.

    (1978)
  • B.V. Zlokovic et al.

    Measurement of solute transport across the blood-brain barrier in the perfused guinea pig brain: Method and application to N-methyl-α-aminobutyric acid

    J. Neurochem.

    (1986)
  • Y. Takasato et al.

    An in situ brain perfusion technique to study cerebrovascular transport in the rat

    Am. J. Physiol.

    (1984)
  • D. Triguero et al.

    Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins

    J. Neurochem.

    (1990)
  • T. Terasaki et al.

    In vitro transport of a dynorphin-like analgesic peptide, E-2078, through the blood-brain barrier: An application of brain microdialysis

    Pharm. Res.

    (1991)
  • W.M. Pardridge et al.

    Rapid sequestration and degradation of somatostatin analogues by isolated brain capillaries

    J. Neurochem.

    (1985)
  • W.M. Pardridge

    Brain metabolism: A perspective from the blood-brain barrier

    Physiol. Rev.

    (1983)
  • K.L. Audus et al.

    Characterization of an in vitro blood-brain barrier model system for studying drug transport and metabolism

    Pharm. Res.

    (1986)
  • L.L. Rubin et al.

    A cell culture model of the blood-brain barrier

    J. Cell Biol.

    (1991)
  • W.H. Oldendorf

    Carrier-mediated blood-brain barrier transport of short-chain monocarboxylic organic acids

    Am. J. Physiol.

    (1973)
  • W.H. Oldendorf

    Blood-brain barrier permeability to lactate

    Eur. Neurol.

    (1972)
  • T. Terasaki et al.

    Transport of monocarboxylic acids at the blood-brain barrier: Studies with monolayers of primary cultured bovine brain capillary endothelial cells

    J. Pharmacol. Exp. Ther.

    (1991)
  • T. Terasaki et al.

    In vitro evidence for carrier-mediated uptake of acidic drugs by isolated bovine brain capillaries

    J. Pharm. Pharmacol.

    (1991)
  • S.E. Buchalter et al.

    Regulation of lactate metabolism in vivo

    Diabetes Metab. Rev.

    (1989)
  • A. Alm et al.

    Lactate transport through blood-retinal and the blood-brain barrier in rats

    Ophthalmic Res.

    (1985)
  • L. Aubert et al.

    Molecular features of organic anion permeability in ox red blood cell

    J. Physiol.

    (1975)
  • A.P. Halestrap

    Transport of pyruvate and lactate into human erythrocytes

    Biochem. J.

    (1976)
  • B. Deuticke

    Monocarboxylate transport in erythrocytes

    J. Membrane Biol.

    (1982)
  • R.C. Poole et al.

    N-Terminal protein sequence analysis of the rabbit erythrocyte lactate transporter suggests identity with the cloned mono-carboxylate transport protein MCT1

    Biochem. J.

    (1994)
  • G.M. Knudsen et al.

    Kinetic analysis of the human blood-brain barrier transport of lactate and its influence by hypercapnia

    J. Cerebral Blood Flow Metab.

    (1991)
  • J.E. Cremer et al.

    Kinetics of blood-brain barrier transport of pyruvate, lactate and glucose in suckling, weanling and adult rats

    J. Neurochem.

    (1979)
  • A. Gjedde et al.

    Induction processes in blood-brain transfer of ketone bodies during starvation

    Am. J. Physiol.

    (1975)
  • A. Tsuji et al.

    Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier

    J. Pharmacol. Exp. Ther.

    (1993)
  • A. Saheki et al.

    In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors

    Pharm. Res.

    (1994)
  • M. Yamazaki et al.

    Na+-independent multispecific anion transporter mediates active transport of pravastatin into rat liver

    Am. J. Physiol.

    (1993)
  • I. Tamai et al.

    Proton-cotransport of Pravastatin across intestinal brush-border membrane

    Pharm. Res.

    (1995)

    • Cited by (103)

    • Neurotoxic effect of nalufin on the histology, ultrastructure, cell cycle and apoptosis of the developing chick embryo and its amelioration by selenium

      2021, Food and Chemical Toxicology
      Citation Excerpt :

      In fact, lipid solubility isn't the leading factor affecting the ability of a molecule to cross the blood brain barrier. Active transport, relative size and surface activity are very important factors regarding passing the blood-brain barrier (Ramlakhan and Altman, 1990; Tamai and Tsuji, 1996). It has been reported that morphine reaches the brain and diffuse to the endothelial cells of the blood-brain barrier through active transport.

    • Carrier-mediated transportation through BBB

      2018, Brain Targeted Drug Delivery Systems: A Focus on Nanotechnology and Nanoparticulates

    • Beyond the blood-brain barrier

      2018, Nanotechnology-Based Targeted Drug Delivery Systems for Brain Tumors

    • Quantitative structure-activity relationship prediction of blood-to-brain partitioning behavior using support vector machine

      2012, European Journal of Pharmaceutical Sciences
      Citation Excerpt :

      In the ordinary brain, the passage of compounds over the BBB is extremely limited and homeostasis within the perceptive environment of the brain parenchyma can be preserved. In the case of effective CNS acting drugs, knowledge of the diffusion of drugs through the BBB is needed to screen potential therapeutic agents and to improve the side effect profile of drugs with tangential activity (Tamai and Tsuji, 1996; Lacombe et al., 2010; Muster et al., 2008). The extent to which drug molecules cross from the blood into the brain is governed by two physiologically and anatomically related systems, BBB and the blood–cerebral spinal fluid (CSF) barrier, which form two pathways by which drug compounds partition between plasma and brain tissue.

    • Polysorbate 80 coated poly (ε-caprolactone)-poly (ethylene glycol)-poly (ε-caprolactone) micelles for paclitaxel delivery

      2012, International Journal of Pharmaceutics

    • Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals

      2011, International Journal of Pharmaceutics
    View all citing articles on Scopus
    View full text
    Copyright © 1996 Published by Elsevier B.V.